29th April – 1st May 2024 | Amsterdam, Netherlands

www.neoantigen-summit.com

LIMITED PASSES REMAINING - REGISTER NOW

7th International

NEOANTIGEN Summit

Accelerating Robust, Durable & Clincally Effective Neoantigens to the Patient



Supercharging Neoantigen-Based Therapeutics & Cancer Vaccines Through Optimised Neoantigen Prediction & Streamlined Clinical Translation for Faster Approval

Expert Speakers Include:

Andrew Allen
Chief Executive Officer & President
Gritstone Bio

Maarten Slagter
Scientist (Computational) Cancer Genomics
CureVac

Jian Yan
Vice President, Research & Discovery
Geneos Therapeutics

Giulia Longinotti
Director TCR Discovery Platform
Medigene Immunotherapies GmbH

Mikkel Wandahl Pedersen
Chief Scientific Officer
Nykode Therapeutics

Guido Leoni
Lead of Bioinformatics
Nouscom Srl

Proud to Partner With: ALMAC Partnering to Advance Human Health · NEC NEC OncoImmunity AS · Personalis · BCN peptides The art of making peptides · intavis Peptide Services · Seqalis · PathoQuest

+44 (0)20 3141 8700 info@hansonwade.com
www.neoantigen-summit.com RNA Therapeutics & Vaccines
hansonwade

Welcome to the 7th International Neoantigen Summit

7th International NEOANTIGEN Summit

29th April – 1st May 2024
Amsterdam, Netherlands

The neoantigen field is having a pivotal year with a surge of new investments, collaborations and positive clinical readouts such as those by **Nykode Therapeutics** & **Regeneron** and **Transgene** & **NEC's**. However, key challenges remain before they truly become blockbuster therapies for patients in need.

Building upon the momentum and progress in the field, the **7th International Neoantigen Summit 2024** returns to Amsterdam to unite the global neoantigen community to overcome **identification**, **prediction**, and **translational challenges** that are holding back the full potentials of this class of therapies.

Join leading neoantigen trailblazers from the likes of **Gritstone Bio**, **CureVac**, **Medigene**, **Geneos Therapeutics** & **Nykode Therapeutics** at the only end to end, industry dedicated neoantigen meeting covering the depth and breadth of the field from **mRNA- to DNA- and viral vector- based vaccines** as well as **novel cell therapies** with the true potentials to develop safe, durable and effective off-the-shelf or individualized neoantigen immunotherapeutics and vaccines for cancer patients.

Don't miss out on your opportunity to hear first-hand from world-class experts of biopharma as they navigate:

- Improving identification and prediction of highly immunogenic, tumour-specific and clinically relevant neoantigens with tools such as bioinformatics, machine learning & beyond
- Latest breakthroughs from clinical readouts from global frontiers pioneering the application of neoantigen derived vaccines and therapies in patients with solid tumours
- The future promise of combination therapies & modalities towards treatment with enhanced immunogenicity and reduced resistance
- Strategies to reduce turnaround time & improve cost-effectiveness for more successful translation into the clinic

With 3-days of dedicated content, 25+ speakers and 80+ Directors, Heads, VPs and C-level executives in **Cancer Vaccines, Immunotherapies, Bioinformatics and Translational Immunology,** join us to ensure you are ahead of the curve with advancements. This meeting will provide you with actionable insights to take to your team to your team to differentiate and accelerate the translation and approval of your assets towards effective neoantigen derived therapies for patients globally.

2024 Event in Numbers

80+ Attendees

25+ World-Class Speakers

15+ Data-Driven Presentations

8+ Hours of Networking

3 Jam-Packed Days of Content

Your Guide to Neoantigen Based Therapies Success

Delve into the latest advances in bioinformatic tools and machine learning techniques towards **accurate prediction of neoantigen targets** to unlock more immunogenic therapies with **CureVac** & **Epitopea**

Hear novel and brand-new clinical data insights to **stay ahead of the curve and fast-track your neoantigen-based therapies** towards approval with **Gritstone Bio**, **Geneos Therapeutics** & **Imvax**

Drive the success of personalised medicines by addressing the **challenges of turnaround time, cost and tumour** heterogeneity with **Nykode Therapeutics** & **BlueSphere Bio**

Improve your combination strategy by gaining a better understanding of the **mechanism of action for novel combination therapies** for more effective treatment of solid tumours with **Precision Biologics, Inc.** & **Replicate Bioscience**

Leverage innovative delivery platforms and vaccine design for more targeted neoantigen vaccines towards the patients in need with **Nykode Therapeutics** & **Nouscom Srl**

+44 (0)20 3141 8700 info@hansonwade.com
www.neoantigen-summit.com RNA Therapeutics & Vaccines
hansonwade

Your Expert Speakers

7th International NEOANTIGEN Summit
29th April – 1st May 2024
Amsterdam, Netherlands

Alastair Hay
Vice President, Peptides
Almac Sciences

Erkut Bahceci
Chief Medical Officer
BlueSphere Bio

Dirk Hadaschik
Chief Scientific Officer
CeCaVa GmbH & CO. KG

Jeroen Kneppers
Scientist (Computational) Cancer Genomics
CureVac

Maarten Slagter
Scientist (Computational) Cancer Genomics
CureVac

Jon Moore
Chief Scientific Officer & Co-Founder
Epitopea

Alfred Slanetz
President & Chief Executive Officer
Geneius Biotechnology, Inc.

Jian Yan
Vice President - Research & Discovery
Geneos Therapeutics

Wayne Paes
Senior Scientist
Grey Wolf Therapeutics

Andrew Allen
Chief Executive Officer & President
Gritstone Bio

Mark Exley
Chief Scientific Officer
Imvax

Giulia Longinotti
Director TCR Discovery Platform
Medigene Immunotherapies GmbH

Marc van Dijk
Chief Scientific Officer
MiNK Therapeutics

Devabhaktuni Srikrishna
Neoantigen Expert

Guido Leoni
Lead of Bioinformatics
Nouscom Srl

Agnete Fredriksen
Co-Founder & Chief Buisness Officer
Nykode Therapeutics

Nicolas Poirier
Chief Executive Officer & Chief Scientific Officer
OSE Immunotherapeutics

Eric Halioua
President & Chief Executive Officer
PDC*Line Pharma

Philip Arlen
President & Chief Executive Officer
Precision Biologics, Inc.

Zelanna Goldberg
Chief Medical Officer
Replicate Bioscience

Martin Löwer
Deputy Director Biomarker Development
TRON

Eniko Toke
Chief Scientific Officer
Treos Bio Ltd.

Paula Pohlmann
Associate Professor
University of Texas MD Anderson Cancer Centre

Bruno Fant
Chief Technology Officer
myNEO Therapeutics

Christian Stumpp
Head of Business Development
Intavis Peptide Services GmbH

Bauke Anninga
Investment Director
M Ventures

Nancy Groot
Associate Director, Biopharma Business Development
Personalis

Helena Sabata
Business Development
BCN Peptides

Pre-Conference Workshop Day
Monday 29th April 2024

Check-In Opens & Morning Welcome Coffee & Light Breakfast 8.00

Workshop A 9.00

Unearthing the Dark Antigenome & Leveraging Machine Learning to Accurately Prioritise Neoantigens

High throughput sequencing technologies are allowing for an ever-increasing resolution of tumour genome characterisation, offering exciting windows of opportunity for (personalised) cancer vaccines. How should we identify the most promising targets, with the highest probability of (T cell) immunogenicity? Are there new targets in the genome that were previously left not considered? What roles can machine learning and AI play in prioritising candidates among the plethora of choices that are available for most patients with cancer? What are key considerations in applying these technologies correctly?

In this workshop we will discuss our efforts in both antigen discovery and computational validation of immunogenicity at CureVac. During presentations, we'll identify controversial topics and call for audience input.

Discovery of Unannotated Small Open Reading Frame Tumour Associated Antigens

- smORF TAA antigen discovery
- Decreasing search spaces, assessing translational potential
- Experimental validation

Machine learning for Neoantigen Identification

- Predictive features to consider in immunogenicity prediction
- Robust machine learning to learn the characteristics of immunogenic neo-epitopes
- Limitations to the currently available training data and how to address them

Workshop Leaders

Maarten Slagter
Scientist (Computational) Cancer Genomics
CureVac

Jeroen Kneppers
Scientist (Computational) Cancer Genomics
CureVac

Morning Break & Networking 11.00

Workshop B 12.00

Delving into the Tumour Microenvironment to Improve Understanding of the Immunosuppressive Environment to Increase Effectivity of Neoantigen Therapies

Due to the great heterogeneity of tumours, they can evolve capabilities to allow them to escape and evade the immune system. Moreover, the tumour microenvironment may have compounds or signals which block interactions between therapies and the tumour. Therefore, in order to create the most effective and immunogenic therapies, these mechanisms need to be understood further to enable adaptation to the tumour and its microenvironment.

- Navigating the compounds in the tumour microenvironment which help it overcome the immune system.
- Analysing the presence of microbial species which can impact the efficacy of the therapies.
- Improving awareness of tumour microenvironment to reduce failures.
- How to overcome the challenge of tumour immune escape by targeting multiple neoantigens?
- How to design vaccines and therapeutics to face challenges of tumour immune escape?
- Are there additional signals to identify to ensure success of the therapies?

Workshop Leader

Alfred Slanetz
President & Chief Executive Officer
Geneius Biotechnology, Inc.

Pre-Conference Workshop Day
Monday 29th April 2024

Lunch & Networking 14.00

Workshop C 15.00

Discovering the Optimal Clinical Setting for Achieving Positive & Accurate Clinical Results to Streamline Candidate Approval

To successfully carry out trials for neoantigen therapies, the field needs to understand what the best clinical setting is and what conditions should be used to get the most accurate and reliable results. This enable neoantigen therapies to be fast-tracked through the clinic in order to get to the patients in need faster.

- What learnings can be taken from the current clinical trials which have occurred with neoantigen therapies?
- How to design the optimal clinical conditions – low tumour burden vs high tumour burden, hot tumours vs cold tumours?
- What to do to maximize the chance of getting a signal?
- Analysing optimum clinical trial conditions for personalised vaccines and combination therapies.
- What is the process for registration in different regions?
- What learnings can be taken from the current clinical trials which have occurred with vaccine and neoantigen therapies?
- How to design the optimal clinical conditions – untreated vs pretreated, metastases stage/location/size, immune cell infiltration, ECOG status? What to do to maximize the chance of getting a signal?

Workshop Leaders

Eric Halioua
President & Chief Executive Officer
PDC*Line Pharma

Devabhaktuni Srikrishna
Neoantigen Expert

Paula Pohlmann
Associate Professor
University of Texas MD Anderson Cancer Centre

End of Pre-Conference Workshop Day 17.00

> "Sharing of ideas and expertise to make neoantigen based vaccines and therapies more likely to succeed in the clinic and transform cancer care."
>
> President & Chief Executive Officer,
> **Geneius Biotechnology, Inc.**

Conference Day One
Tuesday 30th April 2024

7th International NEOANTIGEN Summit
29th April – 1st May 2024
Amsterdam, Netherlands

8.00 Check-In Opens & Morning Welcome Coffee & Light Breakfast

Andrew Allen
Chief Executive Officer & President
Gritstone Bio

8.50 **Chair's Opening Remarks**

Exploring Novel Prediction Strategies & Targets to Improve Immunogenic Effects Leading to More Effective Neoantigen Therapies

Jon Moore
Chief Scientific Officer & Co-Founder
Epitopea

9.00 **Building High-Performance Off-the-Shelf Therapeutic Vaccines Based on Shared TSAs from the Cryptic Genome**

- Epitopea is exploiting a new family of mass spec identified wild-type TSAs derived from so-called non-coding DNA that represent the major opportunity for T cell-mediated control of tumours
- Configured into a LNP-mRNA vaccine, the mouse counterparts of these antigens control tumour growth as single agents
- We are configuring human cryptic TSAs into highly effective cancer vaccines, where each class I TSAs within can be confirmed to be presented by mass spectroscopy

Erkut Bahceci
Chief Medical Officer
BlueSphere Bio

9.30 **Personalised T-cell Therapy for Solid Tumours: Novel Platforms to Create Patient-Specific TCR Therapies Targeting Neoantigens**

- Uncovering NEOXpress Platform to identify, clone and express neoantigens for Personalised therapies
- Highlighting TCXpress platform to identify effective neoantigen targeting TCRs
- Showcasing a quick and cost effective process to produce TCR therapies against neoantigens

Martin Löwer
Deputy Director Biomarker Development
TRON

10.00 **Detecting New Mutation Targets for Developing Effective Personalised Cancer-Immuno-Therapies**

- Creating bioinformatic tools to detect new potential targets for personalised therapies
- Evaluating the response caused by these new neoantigens
- Using AI and machine learning to improve the success rate of target detection

Wayne Paes
Senior Scientist
Grey Wolf Therapeutics

10.30 **First-In-Class Inhibitors of ERAP1 Generate Novel Targets for MHC-I-Directed Therapies**

- Inhibition of ERAP1 by first-in-class small molecule inhibitors significantly alters the antigenic repertoire of cancer cells
- Novel ERAP1-independent epitopes are presented on MHC-I molecules for immune recognition
- Cytotoxic T cell recognition of these novel epitopes mediates tumor cell lysis

Helena Sabata
Business Development
BCN Peptides

11.00 **BCN Peptides: Cutting-Edge Technology for the Manufacturing of Personalized Neoantigen Peptide Therapies**

- BCN Peptides is a European privately held company focused on the GMP industrial manufacture of bioactive peptides. Our Peptide-based Personalized Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology
- Our software enables full GMP control through online management of sequences, real-time process monitoring, and automatized revision and CoA issuance
- Peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses and allows the production of safe and effective individualized neoantigen peptide therapies

11.10 Morning Break & Speed Networking

- This session is your opportunity to get face-to-face with many of the brightest minds working in the Neoantigen field, and establish meaningful business relationships to pursue for the rest of the conference

Driving More Successful Approvals by Leveraging Clinical Data & Investment Insights to to Fast-track Therapies to Patients

12.00 **Fireside Chat: Discussing Investment Opportunities for Better Understanding of What Venture Capitalists are Looking for to Enable Advancement of Neoantigen Therapies**

- What are the risk factors that investors are concerned about causing them to withold?
- How to develop the most effective data packages for investors?
- How do investors view neoantigen companies?

Eric Halioua
President & Chief Executive Officer
PDC*Line Pharma

Bauke Anninga
Investment Director
M Ventures

Conference Day One
Tuesday 30th April 2024

Andrew Allen
Chief Executive Officer & President
Gritstone Bio

12.30 Clinical Trial Data with a Personalised Neoantigen Cancer Vaccine in Metastatic Colorectal Cancer

- We have developed a heterologous prime-boost personalised neoantigen cancer vaccine using adenoviral prime and self-amp mRNA boost vectors
- Phase 1 data demonstrated good safety, immunogenicity and early signals of clinical benefit
- A randomised, controlled phase 2 trial in metastatic colorectal cancer is expected to report preliminary data from a subset of patients in 1 Q24

Eniko Toke
Chief Scientific Officer
Treos Bio Ltd.

13.00 Uncovering an Off-the-Shelf Peptide-Based Cancer Vaccine

- Highlighting a novel platform used which takes into account the tumour heterogeneity as well as patient heterogeneity
- Evaluating clinical trials which took place in the most difficult-to-treat colorectal cancer (MSS mCRC)
- Showcasing correlation studies for the identification of a candidate predictive biomarker

Christian Stumpp
Head of Business Development
Intavis Peptide Services GmbH

13.30 Accelerating Personalized Peptide Vaccine Trials

- What are current challenges when conducting trials on personalized peptide vaccines?
- How do you choose the right CDMO to meet those challenges?

13.40 Lunch & Networking

Spotlighting Personalised Medicines & Navigating Challenges of Time & Cost to Improve Feasibility of Advanced Cancer Treatments

Alastair Hay
Vice President, Peptides
Almac Sciences

14.30 Building a High Throughput Manufacturing Facility for Personalised Vaccines

- Key considerations for High Throughput manufacturing
- Technical, quality and regulatory considerations
- Future directions

14.40 Roundtable Discussion: Discussing Strategies to Reduce Turnaround Time & Improve Cost-Effectiveness for More Successful Translation into the Clinic

- Which stage of production does the field need to focus on improving to accelerate the turnaround time?
- What strategies are the field currently implementing to improve the cost restraints of personalised medicines?
- Are there novel manufacturing methods which can be used to reduce turnaround time?

Erkut Bahceci
Chief Medical Officer
BlueSphere Bio

15.40 Afternoon Networking Break

Jian Yan
Vice President - Research & Discovery
Geneos Therapeutics

16.10 Personalised DNA Neoantigen Vaccine & Pembrolizumab in Advanced Hepatocellular Carcinoma

- Updates on clinical response data from GNOS-PV02 Phase 1b/2a clinical trial in 2L advanced HCC
- Highlighting pharmacodynamic and biomarker data from personalised DNA cancer vaccine in combination with Pembrolizumab
- What are critical factors for clinical translation of personalised therapies?

Nancy Groot
Associate Director, Biopharma Business Development
Personalis

16.40 Personalis: Best-in-Class NGS Partner for Individualised Neoantigen-based Therapy Design and Response Monitoring

- ImmunoID NeXT; multidimensional view of the tumour and the TME from a single sample, including comprehensive neoantigen identification (with accelerated TATs)
- NeXT Personal; ultra-sensitive, tumour-informed liquid biopsy assay for MRD detection and therapy response monitoring, with simultaneous variant tracking

Mark Exley
Chief Scientific Officer
Imvax

16.50 Goldspire™ Personalised Tumour-Derived Late Stage Clinical Immunotherapy Platform Uses the Full Antigenic Signature of Solid Tumour to Induce Durable Anti-Tumour Immunity

- Goldspire™ personalised tumour-derived immunotherapy is safe and clinically active in glioblastoma
- Goldspire™ is active in multiple solid tumour preclinically, induces durable systemic anti-tumour immunity
- Goldspire™ is currently in late stage clinical development in glioblastoma

Andrew Allen
Chief Executive Officer & President
Gritstone Bio

17.20 Chairs Closing Remarks & End of Conference Day One

Conference Day Two
Wednesday 1st May 2024

8.50 Morning Coffee & Light Breakfast

Dirk Hadaschik
Chief Scientific Officer
CeCaVa GmbH & CO. KG

9.20 **Chair's Opening Remarks**

Supercharging Neoantigen Vaccine Platforms Towards Patients in Need by Optimising Design & Delivery for More Potent Therapies

Bruno Fant
Chief Technology Officer
myNEO Therapeutics

9.30 **Bringing Novel Class of Vaccine Targets into Development - Camyopeptides Derived from Tumour-Specific lncRNAs**

- Results from the profiling of over 1500+ tumour biopts and neoantigen landscapes
- First glance at immunological responses revealing first-in-class potential of shared tumor targets
- Designing the mRNA-LNP cancer vaccine

Agnete Fredriksen
Co-Founder & Chief Buisness Officer
Nykode Therapeutics

10.00 **Optimising RNA/DNA-Based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy**

- How to improve immune responses by targeting epitopes to antigen presenting cells
- Impact of neoepitope arrangement on immunogenicity and expression/secretion
- How to effectively compile the sequences, is it more effective to split the load or to add all the sequences in one molecule?

Guido Leoni
Lead of Bioinformatics
Nouscom Srl

10.30 **Design of Viral Vectored Vaccines Targeting Multiple Tumour Neoantigens to Elicit Potent & Effective Anti-tumour Immune Response**

- Design of a potent heterologous prime/boost vaccination platform based on viral vectors (non-human Great Ape Adenovirus and MVA) encoding an unprecedented number of tumour neoantigens
- Demonstrating induction of strong and high-quality T cell immune response in vaccinated patients
- Dissecting the contribution of vaccine-induced T cells to clinical responses

11.00 Morning Networking Break & Scientific Poster Session

Illuminating Shared Neoantigen Therapies to Induce More Durable & Robust Immunity in a Larger Patient Population

Giulia Longinotti
Director TCR Discovery Platform
Medigene Immunotherapies GmbH

12.00 **KRAS Mutation-Specific TCR-T Cells are Empowered for Improved Multi-Functionality & Durability by Inclusion of a Costimulatory Switch Protein**

- Generation of 3S TCRs from naïve repertoires of healthy donors that recognise KRAS-specific mutations (mKRAS) display high specificity, high sensitivity and an excellent safety profile in recognition of mKRAS-expressing tumour cells
- Co-expression of a PD1-41BB Costimulatory Switch Protein (CSP) armors TCR-T cells against PD-L1-mediated inhibition and enhances multiple cellular functions through intracellular activation of the 41BB costimulatory pathway, enabling TCR-T cells to function better in a hostile tumour microenvironment
- Our automated method of producing enriched CD8+ TCR-T cells yields Drug Products with enhanced capacity to proliferate and persist upon repeated encounter with PD-L1-expressing tumour cells, supporting important parameters associated with durability

Conference Day Two
Wednesday 1st May 2024

Nicolas Poirier
Chief Executive Officer & Chief Scientific Officer
OSE Immunotherapeutics

12.30 **Neoepitopes Cancer Vaccine Monotherapy Positive Efficacy Randomised Phase 3 results in Non-Small Cell Lung Cancer with Resistance to Immunotherapy**

- Tedopi is a tumour-specific activating immunotherapy based on highly-selected and optimised tumour neoepitopes
- Positive clinical efficacy of Tedopi versus chemotherapy in a randomised Phase III trial in Non-Small Cell Lung Cancer in patients with secondary resistance after failure of checkpoint inhibitors: Significantly better survival: 44% overall survival at 1-year, versus 27% with chemotherapy; Significantly better safety profile: 3-fold less severe Grade 3-5 adverse events and significantly better quality of life.

Marc van Dijk
Chief Scientific Officer
MiNK Therapeutics

13.00 **Targeting Neoantigens with Invariant Natural Killer T Cells**

- MiNK therapeutics is developing iNKT-based allogeneic cell therapy products for cancer. Invariant Natural Killer T cells (iNKT) recognise glycolipids presented on CD1d through their invariant TCR.
- iNKT cells can be engineered to stably express a 2nd TCR, and both TCRs are fully functional
- We are developing a portfolio of phospho-peptide neoantigen-specific TCRs for iNKT-based applications

13.30 **Lunch & Networking**

Optimising Combination Therapies by Deep Diving into Mechanism of Action & Combination Strategies for More Successful, Effective & Safer Therapeutics

14.30 **Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need**

- Which of the current state of the art immunotherapies are likely to combine well with neoantigen therapies?
- Beyond checkpoint inhibitors, what combinations seem the most promising?
- Are there certain combinations which work better for different stages of cancer?
- Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins.

Philip Arlen
President & Chief Executive Officer
Precision Biologics, Inc.

Devabhaktuni Srikrishna
Neoantigen Expert

Mark Exley
Chief Scientific Officer
Imvax

Zelanna Goldberg
Chief Medical Officer
Replicate Bioscience

15.30 **Afternoon Networking Break**

Philip Arlen
President & Chief Executive Officer
Precision Biologics, Inc.

16.00 **Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies**

- What is the mechanism of action of a neoantigen antibody being used in combination?
- How to effectively use the neoantigen antibody, should it be applied before the checkpoint inhibitor or after?
- Would it be beneficial to combine with more than one other approach?

Zelanna Goldberg
Chief Medical Officer
Replicate Bioscience

16.30 **Multitargeted Self-Replicating RNA for Off-The-Shelf Cancer Precision Immunotherapeutics**

- Replicate Bioscience's self-replicating RNA platform supports a unique and powerful approach to preventing and reversing the emergence of common acquired resistance mutations
- Using multigenic self-replicating RNA we have created precision immunotherapeutics that can be dosed in combination with SOC approved cancer agents, thus maintaining selective pressure on the tumour
- Mechanistically, the combination of the Replicate immunotherapy and the SOC creates a lose-lose situation wherein wild-type tumour clones are controlled by the SOC treatment and resistance mutant positive clones die by the precision immunotherapeutic. We term this synthetic immune lethality

Dirk Hadaschik
Chief Scientific Officer
CeCaVa GmbH & CO. KG

17.00 **Chairs Closing Remarks & End of the 7th International Neoantigen Summit 2024**

Our 2024 Partners

Innovation Partner

Almac has been supplying peptides to the research community and for clinical trials for > 20 years. The field of personalised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs. Think Almac for peptide excellence.

www.almacgroup.com

Industry Partner

NEC Bio B.V. was founded in 2023 and is developing AI-empowered personalized neoantigen targeting cancer vaccines as well as prophylactic infectious disease vaccines. Its subsidiary NEC OncoImmunity AS (Oslo, Norway) is a leader in proprietary machine learning algorithms and data to predict antigen presentation and immunogenicity. The software is applied to the selection of patient specific targets in immuno-oncology clinical trials and to the identification of epitope targets for infectious diseases. NEC Bio Therapeutics (Mannheim, Germany) is conducting clinical trials with its proprietary oral bacteria-based DNA vaccination platform targeting personalized neoantigens in solid tumor patients. Along with other collaborations, NEC Bio is collaborating with Transgene on the virus-based personalized neoantigen product TG4050 in clinical trials in head and neck cancer.

www.linkedin.com/company/nec-bio-bv/

Innovation Partner

At Personalis, our mission is to transform the active management of cancer through personalised testing. For personalised cancer therapies (PCT), ImmunoID NeXT™ powers individualised neoantigen-based therapy design, with NeXT Personal™ providing therapy response monitoring (e.g. an early indication of efficacy). NeXT Personal is designed to detect disease recurrence earlier than ever before, and to monitor ctDNA kinetics with unparalleled sensitivity, driving patient stratification, and enhancing biomarker strategy for drug development. We are driving a new paradigm for cancer management, guiding care from biopsy through the life of the patient, delivering advanced insights, even as cancer evolves over time.

www.personalis.com

Innovation Partner

BCN Peptides, based in Barcelona, is a privately held company focused on the GMP industrial manufacture of bioactive peptides for pharmaceutical and veterinary applications. With over 30 years of experience, our GMP-approved facility focuses on 3 areas of activity: generic peptide synthesis, customized new chemical entities, and production of GMP neoantigen peptides for personalized medicine.

Our Peptide-based Personalized Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. The implementation of automatization systems, together with a fit-for-purpose quality system allows for high-speed production under official GMP certification and complete traceability of the entire process.

www.bcnpeptides.com

GET INVOLVED



Rakkan Said
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Our 2024 Partners

Innovation Partner

Your trusted end-to-end provider of personalized peptide cancer vaccines with 30+ years in peptide synthesis. With expanding facilities for GMP peptide manufacturing and aseptic fill and finish, we offer full peptide drug development: customized research-grade peptides, peptide drug substance and peptide drug product. In combination with our unmatched customer-service and manufacturing speed, you will execute your personalized vaccine trial faster with less worries. Simply contact us for a truly end-to-end peptide trial solution.

www.intavispeptides.com

Exhibition Partner

Seqalis is a Belgian Contract Research Organization. We call upon our state-of-the-art platforms such as a quantitative TCR Seq seamless analysis solution, several complementary cytogenomics technologies for the control of the genomic stability and the integrity of ATMPs and an anatomo-pathology service to provide our clients with top-notch analytical solutions in the neoantigen cancer vaccines and immuno-oncology fields.

www.seqalis.com

Exhibition Partner

PathoQuest is a global CRO providing NGS-based Quality Control testing through its iDTECT® platform of assays for rapid and safe release of biotherapies to patients.

Validated and accepted GMP assays for viral safety and genetic characterization of raw materials, cell and gene therapies, mAbs & vaccines.

Testing available in Paris (France) and in Wayne PA.

For more information, visit

www.pathoquest.com

> “The Neoantigen Summit offers the invaluable opportunity of meeting other experts in the immune oncology space, both from academia and industry. We’re happy to exchange ideas and opinions with the rich community at the meeting.”
>
> Scientists (Computational) Cancer Genomics, **CureVac**

GET INVOLVED



Rakkan Said
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Partner With Us

7th International NEOANTIGEN Summit
29th April – 1st May 2024
Amsterdam, Netherlands

Are you committed to overcoming challenges within the field of neoantigen field?

The **7th International Neoantigen Summit** is your premium opportunity to showcase your expertise, advance your organisation's brand and benchmark yourself as a key thought leader and solutions provider within the community.

The neoantigen field is rapidly evolving with drug developers around the world racing to make the best-in-class immunotherapeutics and cancer vaccines. To achieve this, leading experts are looking for service providers with capabilities in developing **bioinformatic tools for accurate identification of neoantigen targets, assay development for investigating drug efficacy** and **manufacturing of personalised medicines** to facilitate their R&D platforms.

This summit is your opportunity to communicate exciting progress to the decision-makers in the neoantigen field, generate leads, and understand what tools and services the market wants and needs to overcome the challenges of innaccurate prediction of tumorigenic targets and measurement of immunogenic therapeutics and vaccines. You can rely on our ability to advise and deliver the right opportunities for you.

Benefit From Market Intelligence

Hear how and where pharmaceutical companies are looking for services and solutions to facilitate their R&D to match your solutions accordingly

Meet & Network with Industry Pioneers

With a room full of drug developers, meet prospective clients during speed networking breaks and informal networking receptions to fuel commercial opportunities

Position Yourself as an Industry Expert

With the growing landscape of neoantigen biotech companies, this meeting is a dedicated platform to put your independent expertise in front of the key decision-makers in the field

Raise Brand Awareness & Generate Commercial Collaborations

Benefit from pre and post conference exposure to our key opinion leaders and make sure you connect with the hottest prospects

SENIORITY OF ATTENDEES*



- C-Level/VPs – 24%
- Heads/Director – 17%
- Managers/Scientists -23%
- Professor –7%
- Other –29%

TYPES OF COMPANIES ATTENDING*



- Drug Developers
- Academic & Research Institutes
- Healthcare Provider
- Equipment & Service Providers/ Manufacturing

*Statistics Taken from 6th Annual Neoantigen Europe Summit

GET INVOLVED



Rakkan Said
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.neoantigen-summit.com/take-part/register/

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

DISCOVER how leading companies are advancing their pipelines to successfully develop neoantigen based immunotherapeutics and cancer vaccines

ADVANCE your understanding of manufacturing strategies and solutions to accelerate the development of personalised neoantigen therapies

BUILD lasting connections with your community and peers from key pharma and biotech companies to continue advancing the field, in an intimate environment.

Drug Developer Pricing*	Register Now & Pay	On the Door
Conference + Workshop Day	€3,697	€3,797
Conference Only	€2,699	€2,799

Academic Pricing**	Register Now & Pay	On the Door
Conference + Workshop Day	€3,097	€3,197
Conference Only	€2,299	€2,399

Service Provider Pricing	Register Now & Pay	On the Door
Conference + Workshop Day	€4,597	€4,697
Conference Only	€3,599	€3,699

All prices shown in Euros. Please visit the website for full pricing options or email info@hansonwade.com

*To be eligible for this price, the group or individual must be from a biotech or pharma company that has a publicly available pipeline, and does not off pay for services.

**To be eligible for this price, the group or individual must be in full-time academic(s).

Please note: If you are a UK or EU-based company, you may be subject to 21% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Team Discounts***

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5 + Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hotel Novotel Amsterdam City
Europaboulevard 10 - 1083 AD - Amsterdam – Netherlands
For further information or assistance, please visit:
www.novotelamsterdamcity.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom